BiomX shares positive data from first bacteriophage trial

pharmafile | February 23, 2023 | News story | Research and Development  

BiomX has shared data from a new study in cystic fibrosis (CF) patients, assessing whether bacteriophages could be a new therapeutic strategy for resistant bacterial infections. Currently, the results appear positive.

Results from BiomX’s study show that nine patients with CF and chronic Pseudomonas aeruginosa (CF-P.a.) infections had a 95% reduction in bacterial burden, measured by colony forming units at day 15.

Analysists at Ladenburg Thalmann have called the results “impressive” despite only being from the phase 1 portion of the phase1/2a study. The analysists explained that the results show evidence of efficacy with a short seven-day duration of treatment, as well as demonstrating the safety and tolerability of BX004.

Advertisement

Bacteriophages are viruses that only selectively target and kill bacteria. They are being suggested as an alternative to antibiotics as they can provide highly-selective activity against pathogens while simultaneously sparing other positive bacteria in the body.

The phase 2 portion of the study has already begun, with two of the 24 patients already having been dosed. Results from this portion are expected in the third quarter of 2023.

Michael Higgins, Ladenburg Thalmann analysist, commented: “In our view, BiomX appears to have appropriately selected the phages for its cocktail to generate safe and effective results in CF-P.a. patients.”

“While resistance development is inevitable, the rate at which resistance occurs is ~10-fold slower following phage therapy compared with resistance development following antibiotic therapy,” he continued.

 

Betsy Goodfellow


Related Content

No items found
The Gateway to Local Adoption Series

Latest content